Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA:688553)
China
· Delayed Price · Currency is CNY 18.49
+0.75 (4.23%)
Mar 10, 2026, 3:00 PM CST
SHA:688553 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 998.15 | 1,085 | 926.02 | 1,490 | 1,820 | Upgrade
|
| Other Revenue | - | 9.01 | 1.06 | 3.27 | 3.44 | Upgrade
|
| Revenue | 998.15 | 1,094 | 927.08 | 1,493 | 1,824 | Upgrade
|
| Revenue Growth (YoY) | -8.79% | 18.05% | -37.92% | -18.12% | 33.68% | Upgrade
|
| Cost of Revenue | - | 187.58 | 132.75 | 180.12 | 160.19 | Upgrade
|
| Gross Profit | 998.15 | 906.8 | 794.32 | 1,313 | 1,664 | Upgrade
|
| Selling, General & Admin | - | 511.56 | 437.58 | 810.82 | 972.32 | Upgrade
|
| Research & Development | - | 327.72 | 340.76 | 356.19 | 248.21 | Upgrade
|
| Other Operating Expenses | 1,063 | 6.57 | 6.72 | 7.83 | 9.57 | Upgrade
|
| Operating Expenses | 1,063 | 845.82 | 787.93 | 1,176 | 1,230 | Upgrade
|
| Operating Income | -65.05 | 60.98 | 6.39 | 136.66 | 433.49 | Upgrade
|
| Interest Expense | - | -12.4 | -6.7 | -1.18 | -1.06 | Upgrade
|
| Interest & Investment Income | - | 50.23 | 79.73 | 91.18 | 20.16 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.78 | 3.33 | -0.13 | -1.1 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.91 | 0.66 | 1.39 | -5.16 | -4.17 | Upgrade
|
| EBT Excluding Unusual Items | -63.13 | 98.69 | 84.13 | 221.37 | 447.31 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 239.86 | 6.44 | 2.33 | 6.16 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.3 | - | -0.03 | -0.02 | Upgrade
|
| Asset Writedown | - | -9.6 | - | - | - | Upgrade
|
| Other Unusual Items | - | 21.05 | 41.58 | 14.72 | 24.25 | Upgrade
|
| Pretax Income | -63.13 | 349.7 | 132.15 | 238.39 | 477.7 | Upgrade
|
| Income Tax Expense | -38.93 | 33.8 | -7.18 | -10.6 | 31.84 | Upgrade
|
| Earnings From Continuing Operations | -24.2 | 315.9 | 139.33 | 248.99 | 445.86 | Upgrade
|
| Minority Interest in Earnings | - | 9.49 | 0.45 | - | - | Upgrade
|
| Net Income | -24.2 | 325.39 | 139.79 | 248.99 | 445.86 | Upgrade
|
| Net Income to Common | -24.2 | 325.39 | 139.79 | 248.99 | 445.86 | Upgrade
|
| Net Income Growth | - | 132.78% | -43.86% | -44.16% | 29.87% | Upgrade
|
| Shares Outstanding (Basic) | 403 | 423 | 424 | 422 | 372 | Upgrade
|
| Shares Outstanding (Diluted) | 403 | 423 | 424 | 422 | 372 | Upgrade
|
| Shares Change (YoY) | -4.55% | -0.24% | 0.37% | 13.58% | 2.81% | Upgrade
|
| EPS (Basic) | -0.06 | 0.77 | 0.33 | 0.59 | 1.20 | Upgrade
|
| EPS (Diluted) | -0.06 | 0.77 | 0.33 | 0.59 | 1.20 | Upgrade
|
| EPS Growth | - | 133.33% | -44.07% | -50.83% | 26.32% | Upgrade
|
| Free Cash Flow | - | 114.78 | -229.79 | -267.55 | 12.91 | Upgrade
|
| Free Cash Flow Per Share | - | 0.27 | -0.54 | -0.63 | 0.04 | Upgrade
|
| Dividend Per Share | - | 0.463 | 0.213 | 0.235 | 0.211 | Upgrade
|
| Dividend Growth | - | 117.47% | -9.36% | 11.37% | - | Upgrade
|
| Gross Margin | 100.00% | 82.86% | 85.68% | 87.94% | 91.22% | Upgrade
|
| Operating Margin | -6.52% | 5.57% | 0.69% | 9.15% | 23.77% | Upgrade
|
| Profit Margin | -2.43% | 29.73% | 15.08% | 16.67% | 24.45% | Upgrade
|
| Free Cash Flow Margin | - | 10.49% | -24.79% | -17.92% | 0.71% | Upgrade
|
| EBITDA | 11.46 | 137.49 | 65.2 | 184.38 | 468.91 | Upgrade
|
| EBITDA Margin | 1.15% | 12.56% | 7.03% | 12.35% | 25.71% | Upgrade
|
| D&A For EBITDA | 76.51 | 76.51 | 58.81 | 47.72 | 35.43 | Upgrade
|
| EBIT | -65.05 | 60.98 | 6.39 | 136.66 | 433.49 | Upgrade
|
| EBIT Margin | -6.52% | 5.57% | 0.69% | 9.15% | 23.77% | Upgrade
|
| Effective Tax Rate | - | 9.67% | - | - | 6.67% | Upgrade
|
| Revenue as Reported | - | 1,094 | 927.08 | 1,493 | 1,824 | Upgrade
|
| Advertising Expenses | - | - | - | 1 | 3.71 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.